List of Excipients in API olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Cosette Pharmaceuticals Inc | TRIBENZOR | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 | CELLULOSE, MICROCRYSTALLINE | |
| Cosette Pharmaceuticals Inc | TRIBENZOR | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 | CROSCARMELLOSE SODIUM | |
| Cosette Pharmaceuticals Inc | TRIBENZOR | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 | MAGNESIUM STEARATE | |
| Cosette Pharmaceuticals Inc | TRIBENZOR | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 | SILICON DIOXIDE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide
Detailed excipient profiles for olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide
Excipient focus: CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing CROSCARMELLOSE SODIUM
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Bryant Ranch Prepack | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 63629-2240 |
| Bryant Ranch Prepack | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 72162-1516 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing FD&C YELLOW NO. 6
Excipient focus: HYPROMELLOSE 2208
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing HYPROMELLOSE 2208
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing HYPROMELLOSE 2208
Excipient focus: MAGNESIUM STEARATE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing MAGNESIUM STEARATE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 1000
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing POLYETHYLENE GLYCOL 1000
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing POLYETHYLENE GLYCOL 1000
| Company | Ingredient | NDC |
|---|---|---|
| Cosette Pharmaceuticals Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 |
| Daiichi Sankyo Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 65597-114 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing POLYSORBATE 20
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing POLYSORBATE 20
Excipient focus: POLYVINYL ALCOHOL
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing POLYVINYL ALCOHOL
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing POLYVINYL ALCOHOL
Excipient focus: SILICON DIOXIDE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Cosette Pharmaceuticals Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 |
| Daiichi Sankyo Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 65597-114 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing SILICON DIOXIDE
Excipient focus: STARCH, CORN
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing STARCH, CORN
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing TALC
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing TALC
Excipient focus: TITANIUM DIOXIDE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants containing TITANIUM DIOXIDE
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Cosette Pharmaceuticals Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 0713-0874 |
| Daiichi Sankyo Inc | olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | 65597-114 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
